Publications

(Displaying in Reverse Chronological Order)

  1. Research
  2. Publications
  3. Publications
2206
Agrawal S, Kaur KJ, Singh I, Bhade S R, Kaul CL and Panchagnula R. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations International Journal of Tuberculosis and Lung Disease 2005, 9, 1273-1280.
2207
Agrawal S, Kaur, KJ, Singh I, Bhade SR, Kaul CL and Panchagnula R. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size International Journal of Tuberculosis and Lung Disease 2005, 9, 75-80.
2208
Agrawal V, Paul MK and Mukhopadhyay AK. 6-Mercaptopurine and daunorubicin double drug liposome- Preparation, drug-drug interaction and characterization Journal of Liposome Research 2005, 15, 141-155.
2209
Ahmed M, Khanna S and Bharatam PV. Importance of Sulfoxidation in Rapid Racemisation of Glitazones Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry 2005, 44B, 600-606.
2210
Arun KHS, Kaul CL and Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats Cardiovascular Research 2005, 65, 374-386.
2211
Ashokraj Y, Gunjan K, Kaul CL and Panchagnula R. Quality control of anti-tuberculosis fixed dose combination formulations in global market: Part-II (Accelerated stability studies) International Journal of Tuberculosis and Lung Disease 2005, 9, 1266-1272.
2212
Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MVS, Kaul CL and Panchagnula R. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment International Journal of Tuberculosis and Lung Disease 2005, 9, 791-796.
2213
Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MVS, Kaul CL and Panchagnula R. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations International Journal of Tuberculosis and Lung Disease 2005, 9, 697-699.
2214
Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U and Ravi Kumar MNV. Design of Biodegradable Nanoparticles: A Novel Approach to Encapsulate Poorly Soluble Phytochemical Ellagic acid Nanotechnology 2005, 16, 2819-2822.
2215
Besra RC, Rudrawar S and Chakraborti AK. Copper(II) tetrafluoroborate as an extremely efficient catalyst for 1,3-dithiolane/dithiane formation from carbonyl compounds under solvent-free conditions at room temperature Tetrahedron Letters 2005, 46, 6213-6217.
2216
Bharadwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R and Ravi Kumar MNV. Pharmaceutical aspects of polymeric nanoparticles for oral delivery Journal of Biomedical Nanotechnology 2005, 1, 235-258.
2217
Bharatam PV, Patel DS and Iqbal P. Pharmacophoric features of biguanidienes: An Electronic Structure Study Journal of Medicinal Chemistry 2005, 48, 7615-7622.
2218
Bharate SB, Chauthe SK, Bhutani KK and Singh IP. An efficient two-step synthesis of jensenone isolated from Eucalyptus jensenii Synthesis of analogues and evaluation as antioxidants Australian Journal of Chemistry 2005, 58, 551-555.
2219
Bhutani H, Singh S and Jindal KC. Drug-drug interaction studies on first-line anti-tuberculosis drugs Pharmaceutical Development and Technology 2005, 10, 517-524.
2220
Bhutani H, Singh S, Jindal KC and Chakraborti AK. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs Journal of Pharmaceutical and Biomedical Analysis 2005, 39, 892-899.
Information: Duration to be uploaded/incorporated on archival site after the completion of process is 12 months.

2627|148|15